SEC filings
Becton Dickinson (BDX)
Recent filings Becton Dickinson made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000010795All filings on SEC.gov
8-KCurrent report
Results of Operations and Financial Condition
Becton Dickinson reported fourth-quarter fiscal 2026 revenue of $5.3 billion, up 5.4%, and full-year revenue of $19.5 billion, and guided fiscal 2027 to adjusted diluted EPS of $13.10 to $13.30. …
10-QQuarterly report
Quarterly report
Becton Dickinson reported fiscal third-quarter 2026 revenue of $4.98 billion, up 5.4% from $4.73 billion a year earlier, with growth across all four segments led by BioPharma Systems (+6.6%) and Interventional (+6.4%). …
8-KCurrent report
Results of Operations and Financial Condition
Becton Dickinson reported third-quarter fiscal 2026 revenue of $4.98 billion, up 5.4% as reported and 4.4% on a currency-neutral basis, with GAAP diluted EPS of $1.64 and adjusted diluted EPS of $3.23, and raised the midpoint of its…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
Michael D. Garrison, executive vice president and president of Becton Dickinson's Medical Essentials and BioPharma Systems segments, has informed the company he intends to retire after more than 20 years, effective Oct. 2. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Becton Dickinson in Readster
Add Becton Dickinson to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.